孟鲁司特钠联合沙美特罗替卡松对哮喘患者血清炎性因子水平及肺功能的影响  

Impact of Montelukast Sodium Combined with Salmeterol Fluticasone on Serum Inflammatory Factor Levels and Lung Function of Patients with Asthma

作　　者：赵玉仙 李震[1] ZHAO Yuxian;LI Zhen(Department of Respiratory Medicine,Nanyang Second People's Hospital,Nanyang 473000,China)

机构地区：[1]南阳市第二人民医院呼吸内科,河南南阳473000

出　　处：《临床医学工程》2023年第2期169-170,共2页Clinical Medicine & Engineering

基　　金：河南省医学科技攻关计划项目“肺牵张指数联合肺电阻抗成像导向的急性呼吸窘迫综合征肺复张后PEEP滴定”(201703223)。

摘　　要：目的探讨孟鲁司特钠联合沙美特罗替卡松对哮喘患者血清炎性因子水平及肺功能的影响。方法82例哮喘患者随机分为两组,对照组予以沙美特罗替卡松治疗,观察组在对照组基础上予以孟鲁司特钠治疗,比较两组的血清炎性因子水平、肺功能指标及不良反应。结果治疗后,观察组的IL-6、TNF-α、EOS水平均低于对照组,FVC、FEV1及PEF均高于对照组(P<0.05)。两组的不良反应发生率比较,差异无统计学意义(P>0.05)。结论孟鲁司特钠联合沙美特罗替卡松治疗哮喘可明显降低患者的炎性因子水平,促进患者肺功能恢复,且安全性较高。Objective To explore the impact of montelukast sodium combined with salmeterol fluticasone on serum inflammatory factor levels and lung function of patients with asthma.Methods 82 patients with asthma were randomly divided into two groups.The control group was treated with salmeterol fluticasone,and the observation group was treated with montelukast sodium on the basis of the control group.The levels of serum inflammatory factors,lung function indicators and adverse reactions were compared between the two groups.Results After treatment,the levels of IL-6,TNF-αand EOS in the observation group were lower than those in the control group,and FVC,FEV1 and PEF were higher than those in the control group(P<0.05).No statistical difference was found in the incidence of adverse reactions between the two groups(P>0.05).Conclusions Montelukast sodium combined with salmeterol fluticasone in the treatment of asthma can obviously reduce the levels of inflammatory factors of patients,promote the recovery of lung function,and has high safety.

关 键 词：哮喘 孟鲁司特钠 沙美特罗替卡松 炎性因子 肺功能 

分 类 号：R562.25[医药卫生—呼吸系统]